Gynecologic Cancers: Case 2 - Episode 10
As stated above, GOG 240 involved the incorporation of antiangiogenesis therapy with chemotherapy for first-line treatment of recurrent disease. GOG 227C used single-agent bevacizumab for second-line (and greater) treatment of recurrence and demonstrated clinical activity. Recently, the antiangiogenesis agent cedirinib (an oral TKI) has also demonstrated clinical efficacy in this setting.
CASE 2: Cervical Cancer
Stephanie M. is a 48-year-old Caucasian mother of 2 children who works as a dental hygienist.
She presented to her PCP in May 2012 with vaginal discharge and pain during intercourse. Prior medical history was notable for smoking (quit 3 years ago) and well-controlled hypertension. Patient had completed only sporadic cervical screening for the past 10 years.
In September 2014, she presented with worsening abdominal pain and fatigue. CT scan showed diffuse pelvic and aortic adenopathy consistent with disease recurrence. Her renal and hepatic function were adequate.